Cytokine expression in the muscle of HIV‐infected patients: Evidence for interleukin‐1α accumulation in mitochondria of AZT fibers

To evaluate the possible role of cytokines in human immunodeficiency virus (HIV)–associated muscular disorders, we performed immunocytochemistry for interleukin‐1α, ‐1β, and ‐6 and tumor necrosis factor‐α on frozen muscle biopsy specimens from HIV‐infected patients with various myopathies (HIV polymyositis in 5, HIV‐wasting syndrome in 5, zidovudine myopathy in 10) and from seronegative individuals (normal muscle in 2, mitochondrial cytopathies in 10). The HIV‐infected patients showed positive reactivities in vessels (interleukin‐1) and in inflammatory cells (mainly interleukin‐1 and tumor necrosis factor‐α), including perivascular hemosiderin‐laden macrophages in 5 patients. In zidovudine myopathy, a majority of AZT fibers (i.e., ragged‐red fibers with marked myofibrillar changes) showed mild to marked expression of interleukin‐1. Expression of interleukin‐1 in the other mitochondrial myopathies was much weaker. Interleukin‐1β messenger RNA was demonstrated in muscle fibers by in situ hybridization, implying that interleukin‐1 was produced in muscle cells. Immunoelectron microscopy showed that interleukin‐1α was mainly bound to mitochondrial membranes in AZT fibers. Proinflammatory and destructive effects of the studied cytokines might be responsible for several myopathological changes observed in HIV‐infected patients, including inflammation and hemosiderin deposits in muscle tissue, and prominent myofibrillar breakdown in AZT fibers.

[1]  P. Gaulard,et al.  Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. , 1994, Blood.

[2]  A. Hernvann,et al.  Differential elevation of circulating interleukin-1 beta, tumor necrosis factor alpha, and interleukin-6 in AIDS-associated cachectic states , 1994, Clinical and diagnostic laboratory immunology.

[3]  R. Gherardi,et al.  Anti‐NKH‐1 antibody specifically stains unmyelinated fibres and non‐myelinating Schwann cell columns in humans , 1993, Neuropathology and applied neurobiology.

[4]  R. Gherardi,et al.  Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy , 1993, Annals of neurology.

[5]  C. Mhiri,et al.  The spectrum of vasculitis in human immunodeficiency virus-infected patients. A clinicopathologic evaluation. , 1993, Arthritis and rheumatism.

[6]  Josep Maria Salanova Grau,et al.  Human immunodeficiency virus type 1 infections and myopathy: Clicical relevance of zidovudine therapy , 1993, Annals of neurology.

[7]  J. Glass,et al.  Cytokine expression of macrophages in HIV‐1‐associated vacuolar myelopathy , 1993, Neurology.

[8]  Z. Amoura,et al.  Skeletal muscle lymphoma in patients with the acquired immunodeficiency syndrome: a diagnostic challenge. , 1993, Arthritis and rheumatism.

[9]  P. Galanaud,et al.  [Cytokines and AIDS]. , 1993, La Revue du praticien.

[10]  C. Dinarello,et al.  The role of interleukin-1 in disease. , 1993, The New England journal of medicine.

[11]  P. Libby,et al.  Cytokines and growth factors in atherogenesis. , 1992, Archives of pathology & laboratory medicine.

[12]  M. Baudrimont,et al.  Skeletal muscle toxoplasmosis in patients with acquired immunodeficiency syndrome: A clinical and pathological study , 1992, Annals of neurology.

[13]  C. Mhiri,et al.  The HIV wasting syndrome. , 1992, Muscle & nerve.

[14]  J. Glass,et al.  Cytokine expression in the brain during the acquired immunodeficiency syndrome , 1992, Annals of neurology.

[15]  M. Dalakas,et al.  Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[16]  G. Pezeshkpour,et al.  Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies. , 1991, Human pathology.

[17]  M. Baudrimont,et al.  Iron pigment deposits, small vessel vasculitis, and erythrophagocytosis in the muscle of human immunodeficiency virus-infected patients. , 1991, Human pathology.

[18]  C. Geny,et al.  Zidovudine myopathy: A distinctive disorder associated with mitochondrial dysfunction , 1991, Annals of neurology.

[19]  J. Fischer,et al.  The effect of interleukin-1 alpha and the glucocorticoid receptor blocker RU 38486 on total and myofibrillar protein breakdown in skeletal muscle. , 1991, The Journal of surgical research.

[20]  F. Torti,et al.  Iron-independent induction of ferritin H chain by tumor necrosis factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Dalakas,et al.  Immunocytochemical and virological characteristics of hiv‐associated inflammatory myopathies: Similarities with seronegative polymyositis , 1991, Annals of neurology.

[22]  N. Koch,et al.  Tumor necrosis factor alpha regulates expression of the major histocompatibility complex class II-associated invariant chain by binding of an NF-kappa B-like factor to a promoter element , 1990, Molecular and cellular biology.

[23]  B. Baethge,et al.  Interleukin‐1α, interleukin‐2, and soluble interleukin‐2 receptors in polymyositis , 1990 .

[24]  M. Dalakas,et al.  Mitochondrial myopathy caused by long-term zidovudine therapy. , 1990, The New England journal of medicine.

[25]  D. Hatat,et al.  TNF stimulates expression of mouse MHC class I genes by inducing an NF kappa B‐like enhancer binding activity which displaces constitutive factors. , 1989, The EMBO journal.

[26]  K. Sanders,et al.  Participation of Ca currents in colonic electrical activity. , 1989, The American journal of physiology.

[27]  A. Engel,et al.  Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. , 1989, Human pathology.

[28]  M. Feldmann,et al.  Mechanism of immune complex‐mediated damage: induction of interleukin 1 by immune complexes and synergy with interferon‐γ and tumor necrosis factor‐α , 1989, European journal of immunology.

[29]  G. Haraldsen,et al.  Immunofluorescent evidence for presence of interleukin-1 in normal and diseased human skeletal muscle. , 1988, Muscle & nerve.

[30]  Elizabeth A. Craig,et al.  A subfamily of stress proteins facilitates translocation of secretory and mitochondrial precursor polypeptides , 1988, Nature.

[31]  W. Fiers,et al.  Induction of an activation antigen on postcapillary venular endothelium in human skin organ culture. , 1987, Journal of immunology.

[32]  D. Isenberg,et al.  Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy. , 1986, Clinical and experimental immunology.

[33]  Robert C. Hobrs.  Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (Interleukin-1) , 1983 .

[34]  A. Goldberg,et al.  Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. , 1983, The New England journal of medicine.

[35]  G. H. Clowes,et al.  Muscle proteolysis induced by a circulating peptide in patients with sepsis or trauma. , 1983, The New England journal of medicine.

[36]  E. Ascer,et al.  Interleukin-1 and thromboxane release after skeletal muscle ischemia and reperfusion , 1992, Annals of vascular surgery.

[37]  Y. Tsunematsu,et al.  Prognosis of children with virus-associated hemophagocytic syndrome and malignant histiocytosis: correlation with levels of serum interleukin-1 and tumor necrosis factor. , 1991, Acta haematologica.

[38]  R. Fielding,et al.  Increased interleukin 1β in human skeletal muscle after exercise , 1989 .

[39]  N. Koch,et al.  Tumor Necrosis Factor ot Regulates Expression of the Major Histocompatibility Complex Class 11-Associated Invariant Chain by Binding of an NF-KB-Like Factor to a Promoter Element , 2022 .